IP Library Granted Patent US 10,039,773
Granted Patent B2
US 10,039,773 · App. 15/840,066 · Granted Aug 7, 2018

Neridronic acid for treating arthritis

Inventor: Herriot Tabuteau (New York, NY)
Assignee: ANTECIP BIOVENTURES II LLC
A61K31/663A61K9/0019A61K9/0053A61K9/0056A61K9/2004A61K31/573A61K31/675A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,039,773
App. No.
15/840,066
Granted
Aug 7, 2018
Kind
B2
Abstract

Oral dosage forms of osteoclast inhibitors, such as neridronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis.

Claims (30)

1. A method of treating arthritis comprising parenterally administering, in a single dose or in divided doses, about 5 mg to about 500 mg of neridronic acid, in an acid form or a salt form, to a human being suffering from arthritis.

2. The method of claim 1 , wherein the human being has a pain intensity of: 6 or greater measured using the 0-10 numerical rating scale (NRS), or 6 cm or greater using the 10 cm visual analog scale (VAS).

3. The method of claim 1 , wherein the human being has a pain intensity of: 7 or greater measured using the 0-10 NRS, or 7 cm or greater using the 10 cm VAS.

4. The method of claim 1 , wherein the neridronic acid is parenterally administered in at least two divided doses of about 10 mg to about 250 mg per divided dose.

5. The method of claim 1 , wherein the neridronic acid is parenterally administered in at least two divided doses of about 5 mg to about 250 mg per divided dose.

6. The method of claim 5 , wherein the divided doses of the neridronic acid are parenterally administered at an interval of 2, 3, or 4 days.

7. The method of claim 6 , wherein each divided dose contains about 100 mg of the neridronic acid.

8. The method of claim 6 , wherein each divided dose contains about 50 mg to about 150 mg of the neridronic acid.

9. The method of claim 6 , wherein each divided dose contains about 150 mg to about 200 mg of the neridronic acid.

10. The method of claim 6 , wherein each divided dose contains about 200 mg to about 250 mg of the neridronic acid.

11. The method of claim 1 , wherein the neridronic acid is administered intravenously.

12. The method of claim 1 , wherein the neridronic acid is administered daily.

13. The method of claim 1 , wherein the neridronic acid is administered weekly.

14. The method of claim 1 , wherein the neridronic acid is administered monthly.

15. A method of treating arthritis comprising parenterally administering, in a single dose or in divided doses, about 200 mg to about 500 mg of neridronic acid, in an acid form or a salt form, to a human being suffering from arthritis.

16. The method of claim 15 , wherein the neridronic acid is parenterally administered in at least two divided doses.

17. The method of claim 16 , wherein the divided doses of the neridronic acid are parenterally administered at an interval of 2, 3, or 4 days.

18. The method of claim 16 , wherein each divided dose contains about 100 mg of the neridronic acid.

19. The method of claim 16 , wherein each divided dose contains about 50 mg to about 150 mg of the neridronic acid.

20. The method of claim 16 , wherein each divided dose contains about 150 mg to about 250 mg of the neridronic acid.

21. A method of treating arthritis comprising parenterally administering, in a single dose or in divided doses, about 150 mg to about 500 mg of neridronic acid, in an acid form or a salt form, to a human being suffering from arthritis.

22. The method of claim 21 , wherein the neridronic acid is parenterally administered in at least two divided doses.

23. The method of claim 22 , wherein the divided doses of the neridronic acid are parenterally administered at an interval of 2, 3, or 4 days.

24. The method of claim 22 , wherein each divided dose contains about 100 mg of the neridronic acid.

25. The method of claim 22 , wherein each divided dose contains about 50 mg to about 150 mg of the neridronic acid.

26. The method of claim 22 , wherein each divided dose contains about 150 mg to about 250 mg of the neridronic acid.

27. The method of claim 21 , wherein the patient experiences pain relief within about three months after the neridronic acid is administered.

28. The method of claim 21 , wherein the patient has a pain intensity of: 6 or greater measured using the 0-10 NRS, or 6 cm or greater using the 10 cm VAS.

29. The method of claim 21 , wherein the patient has a pain intensity of: 7 or greater measured using the 0-10 NRS, or 7 cm or greater using the 10 cm VAS.

30. The method of claim 21 , wherein the neridronic acid is administered daily.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2018
From: TABUTEAU, HERRIOT
To: ANTECIP BIOVENTURES II LLC
Reel/Frame 044721/0725 →
Continuity (29)
Continuation In Part 15481330 · Apr 6, 2017
Continuation In Part 15074380 · Mar 18, 2016
Division 14607947 · Jan 28, 2015
Continuation 14605822 · Jan 26, 2015
Continuation 14604524 · Jan 23, 2015
Continuation In Part 14536526 · Nov 7, 2014
Continuation In Part 14446184 · Jul 29, 2014
Division 14288716 · May 28, 2014
Continuation In Part 14279299 · May 15, 2014
Continuation 14063979 · Oct 25, 2013
Continuation In Part 13894274 · May 14, 2013
Continuation In Part 15360886 · Nov 23, 2016
Continuation In Part PCTUS2015032739 · May 27, 2015
Continuation PCTUS2014050427 · Aug 8, 2014
Continuation 14279241 · May 15, 2014
Provisional Application 61933608 · Jan 30, 2014
Provisional Application 61646538 · May 14, 2012
Provisional Application 61647478 · May 15, 2012
Provisional Application 61654292 · Jun 1, 2012
Provisional Application 61654383 · Jun 1, 2012
Provisional Application 61655527 · Jun 5, 2012
Provisional Application 61655541 · Jun 5, 2012
Provisional Application 61764563 · Feb 14, 2013
Provisional Application 61762225 · Feb 7, 2013
Provisional Application 61767647 · Feb 21, 2013
Provisional Application 61767676 · Feb 21, 2013
Provisional Application 61803721 · Mar 20, 2013
Provisional Application 62431287 · Dec 7, 2016
Related Publication 20180110789A1 · Apr 26, 2018
Cited By (1)
US 12,653,834